UBS Group
OACCU

UBS Group’s Oaktree Acquisition Corp III Life Sciences Unit OACCU Stock Holding History

UBS Group’s Portfolio OACCU Stock Details OACCU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$104K Hold
9,765
– – ﹤0.01% 6985
2025
Q4 		$104K Sell
9,765
-18
-0.2% -$194 ﹤0.01% 6897
2025
Q3 		$104K Hold
9,783
– – ﹤0.01% 7103
2025
Q2 		$104K Buy
9,783
+300
+3% +$3.16K ﹤0.01% 7210
2025
Q1 		$99K Hold
9,483
– – ﹤0.01% 7058
2024
Q4 		$95.9K Buy
+9,483
New +$95.5K ﹤0.01% 6903

Other funds holding OACCU

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
AC
Athos Capital Hong Kong $324M AUM 16.62% 1-Year Est. Return
CS
Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return
DAM
DLD Asset Management New York $1.1B AUM 4.68% 1-Year Est. Return

UBS Group's OACCU Position: Q1 2026 in Review

UBS Group held its Oaktree Acquisition Corp III Life Sciences Unit (OACCU) position steady in Q1 2026 at 9,765 shares worth $104K. The position accounts for ﹤0.01% of the portfolio, ranked #6985.

UBS Group first reported a position in OACCU in Q4 2024 and has held it in 6 quarters since. The position peaked at $104K in Q3 2025. 6 funds tracked by Wall St. Rank hold OACCU as of Q1 2026.

  • UBS Group held 9,765 shares of Oaktree Acquisition Corp III Life Sciences Unit worth $104K as of Q1 2026.
  • UBS Group left its Oaktree Acquisition Corp III Life Sciences Unit share count unchanged in Q1 2026.
  • Oaktree Acquisition Corp III Life Sciences Unit made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #6985 holding.
  • UBS Group first reported a position in Oaktree Acquisition Corp III Life Sciences Unit in Q4 2024 and has held it in 6 quarters since.
  • UBS Group's Oaktree Acquisition Corp III Life Sciences Unit position peaked at $104K in Q3 2025.
  • 6 funds tracked by Wall St. Rank held Oaktree Acquisition Corp III Life Sciences Unit as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.